
Twenty-two strategic enterprises have signed agreements with the Office for Attracting Strategic Enterprises (OASES) to open or expand operations in Hong Kong.
The latest group marks the sixth cohort under the government’s flagship investment attraction initiative since its launch in 2022, bringing the total number of strategic partners to more than 120.
The South China Morning Post looks at who the latest companies are and the anticipated economic impact.
1. Who are the corporations?
Pfizer, a leading global research-based pharmaceutical and biotechnology company, is among the biggest names in the latest cohort.
Advertisement
Amgen, one of the world’s largest independent biotechnology firms, was founded in 1980 and is headquartered in California.
Other companies in the life and health technology sector include German firm Boehringer Ingelheim, mainland China’s Jiangsu Hengrui Pharmaceuticals and HAYA Therapeutics.
Advertisement
In the transport sector, the government has secured commitments from Chinese ride-hailing giant DiDi and Shanghai-based electric vertical take-off and landing (eVTOL) manufacturer AutoFlight.
Among cloud computing firms establishing a presence in the city is LightSpeed Studios, Tencent Games’ global development arm, which uses Tencent Cloud’s technology stack for development, operations and global scaling.

Don't Miss:
-
PLA stages South China Sea drills days after ‘illegal’ Philippine territorial bid
-
Japan quake evacuees with pets find refuge at Kumamoto animal hospital
-
India and China revive Himalayan trade at high-altitude pass
-
‘It will take time to change smoking culture,’ official says after 1,200 site checks
-
Taiwan’s political parties deadlocked over efforts to boost military drone capacity

Europe sanctioned crypto exchange HTX. Experts say the firm is deploying tactics that could blunt the impact.
China Leapfrogs into Global Biotech
Tension in One of Asia’s Flashpoints